Plain-English translation of NCT06075264 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a topical ointment called artesunate can help treat vulvar high-grade squamous intraepithelial lesions (HSIL)—precancerous changes in the vulvar skin caused by HPV infection. Half of the participants will receive the active medication while the other half receive a placebo (inactive ointment), and researchers will track whether the treatment helps the lesions improve or go away.
Precancerous vulvar lesions can progress to cancer if left untreated, and current treatment options often require invasive procedures. This trial is exploring whether this medication, applied as a simple ointment, might offer a less invasive way to treat these lesions.
You likely qualify if…
You likely don't qualify if…
You would apply the ointment to the affected area for 5 days at a time, four times over 8 weeks (with 2-week breaks between cycles). You can receive the ointment at home via mail or in person, and most dosing visits can be done by telehealth. You'll have follow-up examinations at weeks 8, 18, 6 months, and 12 months—some by in-person vulvar examination and one requiring a minor biopsy procedure at week 18 to check if the lesions have improved.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States